Malnutrition associated with unfavorable outcome and death among South African MDR-TB and HIV co-infected children

International Journal of Tuberculosis and Lung Disease

Volumn 18, Issue 9, 2014, Pages 1074-1079

  Hicks, R M ^a,b   Padayatchi, N ^b   Shah, N S ^a   Wolf, A ^a   Werner, L ^b   Sunkari, V B ^c   O'Donnell, Max R ^a,b  

^a ALBERT EINSTEIN COLLEGE OF MEDICINE   (United States)

^b UNIVERSITY OF KWAZULU NATAL   (South Africa)

^c King DinuZulu Hospital   (South Africa)

Author keywords

HIV AIDS; Multidrug resistant tuberculosis; Pediatric

Indexed keywords

ABACAVIR; AMIKACIN; CAPREOMYCIN; COTRIMOXAZOLE; EFAVIRENZ; ETHAMBUTOL; ETHIONAMIDE; ISONIAZID; KANAMYCIN; LAMIVUDINE; LOPINAVIR PLUS RITONAVIR; OFLOXACIN; RIFAMPICIN; STREPTOMYCIN; ANTI HUMAN IMMUNODEFICIENCY VIRUS AGENT; TUBERCULOSTATIC AGENT;

ARTICLE; CHILD; COHORT ANALYSIS; DISEASE ASSOCIATION; EXTENSIVELY DRUG RESISTANT TUBERCULOSIS; FEMALE; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; MAJOR CLINICAL STUDY; MALE; MALNUTRITION; MIXED INFECTION; MORTALITY; MULTIDRUG RESISTANT TUBERCULOSIS; PRIORITY JOURNAL; RETROSPECTIVE STUDY; RISK FACTOR; SOUTH AFRICA; TREATMENT OUTCOME; AGE; CHILD NUTRITION; CHILD NUTRITION DISORDERS; DEVELOPING COUNTRY; EPIDEMIOLOGY; EXTENSIVELY DRUG-RESISTANT TUBERCULOSIS; HIV INFECTIONS; NUTRITIONAL STATUS; PATHOPHYSIOLOGY; PATIENT REFERRAL; PRESCHOOL CHILD; TIME FACTOR; TUBERCULOSIS, MULTIDRUG-RESISTANT;

AGE FACTORS; ANTI-HIV AGENTS; ANTITUBERCULAR AGENTS; CHILD; CHILD NUTRITION DISORDERS; CHILD NUTRITIONAL PHYSIOLOGICAL PHENOMENA; CHILD, PRESCHOOL; COINFECTION; DEVELOPING COUNTRIES; EXTENSIVELY DRUG-RESISTANT TUBERCULOSIS; FEMALE; HIV INFECTIONS; HUMANS; MALE; MALNUTRITION; NUTRITIONAL STATUS; REFERRAL AND CONSULTATION; RETROSPECTIVE STUDIES; RISK FACTORS; SOUTH AFRICA; TIME FACTORS; TREATMENT OUTCOME; TUBERCULOSIS, MULTIDRUG-RESISTANT;

EID: 84906717203     PISSN: 10273719     EISSN: None     Source Type: Journal    
DOI: 10.5588/ijtld.14.0231     Document Type: Article

References (34)

1. World Health Organization. Global tuberculosis report, 2012. WHO/HTM/TB/2012.6. Geneva, Switzerland: WHO, 2012.
2. Nelson L J, Wells C D. Global epidemiology of childhood tuberculosis. Int J Tuberc Lung Dis 2004; 8: 636-647.
3. Marais B J, Hesseling A C, Gie R P, Schaaf H S, Beyers N. The burden of childhood tuberculosis and the accuracy of community-based surveillance data. Int J Tuberc Lung Dis 2006; 10: 259-263.
4. Chaisson R E, Martinson N A. Tuberculosis in Africa - combating an HIV-driven crisis. N Engl J Med 2008; 358: 1089-1092.
5. Lan N T N, Lademarco M F, Binkin N J, Tung L B, Quy H T, Cj N V. A case series: initial outcome of persons with multidrug-resistant tuberculosis after treatment with the WHO standard retreatment regimen in Ho Chi Minh City, Viet Nam. Int J Tuberc Lung Dis 2001; 5: 575-578.
6. Espinal M A, Kim S J, Suarez P G, et al. Standard short-course chemotherapy for drug-resistant tuberculosis: treatment outcomes in 6 countries. JAMA 2000; 283: 2537-2545.
7. Thomas T A, Shenoi S V, Heysell S K, et al. Extensively drug-resistant tuberculosis in children with human immunodeficiency virus in rural South Africa. Int J Tuberc Lung Dis 2010; 14: 1244-1251.
8. Seddon J A, Hesseling A C, Willemse M, Donald P R, Schaaf H S. Culture-confirmed multidrug-resistant tuberculosis in children: clinical features, treatment, and outcome. Clin Infect Dis 2012; 54: 157-166.
9. Schaaf H S, Shean K, Donald P R. Culture confirmed multidrug resistant tuberculosis: diagnostic delay, clinical features, and outcome. Arch Dis Child 2003; 88: 1106-1111.
10. Mendez Echevarria A, Baquero Artigao F, Garcia Miguel M J, et al. [Multidrug-resistant tuberculosis in the pediatric age group]. An Pediatr (Barc) 2007; 67: 206-211. [Spanish]
11. Fairlie L, Beylis N C, Reubenson G, Moore D P, Madhi S A. High prevalence of childhood multi-drug resistant tuberculosis in Johannesburg, South Africa: a cross sectional study. BMC Infect Dis 2011; 11: 28.
12. Drobac P C, Mukherjee J S, Joseph J K, et al. Community-based therapy for children with multidrug-resistant tuberculosis. Pediatrics 2006; 117: 2022-2029.
13. Condos R, Hadgiangelis N, Leibert E, Jacquette G, Harkin T, Rom W N. Case series report of a linezolid-containing regimen for extensively drug-resistant tuberculosis. Chest 2008; 134: 187-192.
14. Day C B P, Massyn N, Padarath A, English R, eds. District health barometer. Durban, South Africa: Health Systems Trust, 2012.
15. South Africa: Department of Health. Management of drug-resistant tuberculosis policy guidelines. Pretoria, South Africa: Department of Health, 2011.
16. World Health Organization. Guidelines for the programmatic management of drug-resistant tuberculosis. WHO/HTM/2006. 361. Geneva, Switzerland: WHO, 2006.
17. Rüsch-Gerdes S, Pfyffer G E, Casal M, Chadwick M, Siddiqi S. Multicenter laboratory validation of the BACTEC MGIT 960 technique for testing susceptibilities of Mycobacterium tuberculosis to classical second-line drugs and newer antimicrobials. J Clin Microbiol 2006; 44: 688-692.
18. Reisner B S, Gatson A M, Woods G L. Evaluation of mycobacteria growth indicator tubes for susceptibility testing of Mycobacterium tuberculosis to isoniazid and rifampin. Diagn Microbiol Infect Dis 1995; 22: 325-329.
19. Centers for Disease Control and Prevention. Growth charts. Atlanta, GA, USA: CDC, 2010. http://www.cdc.gov/growth-charts/ Accessed June 2014.
20. World Health Organization. WHO case definitions of HIV for surveillance and revised clinical staging and immunological classification of HIV-related disease in adults and children. WC 503.1. Geneva, Switzerland: WHO, 2007.
21. Laserson K F, Thorpe L E, Leimane V, et al. Speaking the same language: treatment outcome definitions for multidrug-resistant tuberculosis. Int J Tuberc Lung Dis 2005; 9: 640-645.
22. Seddon J A, Perez-Velez C M, Schaaf H S, et al. Consensus statement on research definitions for drug-resistant tuberculosis in children. J Pediatric Infect Dis Soc 2013; 2: 100-109.
23. Ettehad D, Schaaf H S, Seddon J A, Cooke G S, Ford N. Treatment outcomes for children with multidrug-resistant tuberculosis: a systematic review and meta-analysis. Lancet Infect Dis 2012; 12: 449-456.
24. Velasco M, Castilla V, Sanz J, et al. Effect of simultaneous use of highly active antiretroviral therapy on survival of HIV patients with tuberculosis. J Acquir Immune Defic Syndr 2009; 50: 148-152.
25. Manosuthi W, Chottanapand S, Thongyen S, Chaovavanich A, Sungkanuparph S. Survival rate and risk factors of mortality among HIV/tuberculosis-coinfected patients with and without antiretroviral therapy. J Acquir Immune Defic Syndr 2006; 43: 42-46.
26. Lawn S D, Myer L, Bekker L G, Wood R. Burden of tuberculosis in an antiretroviral treatment programme in sub-Saharan Africa: impact on treatment outcomes and implications for tuberculosis control. AIDS 2006; 20: 1605-1612.
27. Dheda K, Lampe F C, Johnson M A, Lipman M C. Outcome of HIV-associated tuberculosis in the era of highly active antiretroviral therapy. J Infect Dis 2004; 190: 1670-1676.
28. Orenstein E W, Basu S, Shah N S, et al. Treatment outcomes among patients with multidrug-resistant tuberculosis: systematic review and meta-analysis. Lancet Infect Dis 2009; 9: 153-161.
29. Brust J C, Gandhi N R, Carrara H, Osburn G, Padayatchi N. High treatment failure and default rates for patients with multidrug-resistant tuberculosis in KwaZulu-Natal, South Africa, 2000-2003. Int J Tuberc Lung Dis 2010; 14: 413-419.
30. O'Donnell M R, Padayatchi N, Kvasnovsky C, Werner L, Master I, Horsburgh C R, Jr. Treatment outcomes for extensively drug-resistant tuberculosis and HIV co-infection. Emerg Infect Dis 2013; 19: 416-424.
31. Jaganath D, Mupere E. Childhood tuberculosis and malnutrition. J Infect Dis 2012; 206: 1809-1815.
32. World Health Organization. Guidelines for an integrated approach to the nutritional care of HIV-infected children (6 months-14 years). WC 503.6. Geneva, Switzerland: WHO, 2009.
33. Koyanagi A, Humphrey J H, Ntozini R, et al. Morbidity among human immunodeficiency virus-exposed but uninfected, human immunodeficiency virus-infected, and human immunodeficiency virus-unexposed infants in Zimbabwe before availability of highly active antiretroviral therapy. Pediatr Infect Dis J 2011; 30: 45-51.
34. Trehan I, Goldbach H S, LaGrone L N, et al. Antibiotics as part of the management of severe acute malnutrition. N Engl J Med 2013; 368: 425-435.